



Press Release

ABIONYX Pharma announces its financial agenda for the year 2021

Toulouse, FRANCE, Lakeland MI, UNITED-STATES, January 25, 2021, 8:00 am CET **ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)**, a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2021.

Events	Date*
Cash position and activity update for Q4 2020	February 4, 2021
2020 Annual Results	February 25, 2021
Cash position and activity update for Q1 2021	May 6, 2021
Cash position and activity update for Q2 2021	August 5, 2021
2021 Half Year Results	September 9, 2021
Cash position and activity update for Q3 2021	November 4, 2021

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of metabolic diseases as well as with a HDL targeted drug delivery platform.

Contacts:

NewCap

Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98